Investigating the genetics of appendix cancer
Official title: Genetics of Appendix Cancer: The GAP Study
Run by Vanderbilt-Ingram Cancer Center · NCT05734430 · Data updated 2026-11-12
This study is trying to find out how genetics might play a role in appendix cancer by following adults with the disease for up to six years.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 700 (estimated) |
| Sponsor | Vanderbilt-Ingram Cancer Center Academic / other |
| Locations | 1 site (Nashville, Tennessee) |
| Status | Recruiting |
| Started | November 11, 2022 |
| Main results expected | November 2032 |
| Study ends | November 2034 |
| Registry record updated | April 18, 2025 |
| Trial ID | NCT05734430 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older with a confirmed diagnosis of appendix cancer in the United States.
✕Probably not a fit
Patients who are pregnant, unable to provide informed consent, or do not speak English may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The Genetics of Appendix Cancer (GAP) Study is a prospective cohort study that aims to explore genetic variations linked to appendix cancer in adults aged 18 and older. Participants diagnosed with appendix cancer will be recruited and followed for up to six years, during which their hereditary factors, tumor characteristics, and clinical outcomes will be analyzed. The study will also involve collecting biospecimens and comprehensive data to enhance understanding of this rare cancer type.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding of genetic factors in appendix cancer, potentially guiding personalized treatment strategies.
How similar studies have gone: While the study focuses on a rare cancer type, similar genetic studies in other cancers have shown promise in identifying hereditary factors and improving patient outcomes.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: GAP Social * Known diagnosis of appendix cancer in the United States * Mentally and physically able to consent and participate in the study GAP Vanderbilt * Known diagnosis of appendix cancer * Diagnosed by and/or consulting with a physician/clinical provider participating in the GAP Study * Mentally and physically able to consent and participate in the study GAP Parent * Biological parents (mother and/or father) of individuals actively participating in the GAP Study * Residing in the United States * Mentally and physically able to consent and participate in the study Exclusion Criteria: * Women pregnant at the time of consent * Prisoners * Unable to provide informed consent * Unable to read, write, or complete questionnaires in English
Where it's running
-
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States Recruiting
Study contacts
- Principal investigator: Andreana N Holowatyj, PhD, MSCI — Vanderbilt-Ingram Cancer Center
- Study coordinator: GAP Study Coordinator (Rebecca B.)
- Email: gapcancerstudy@vumc.org
- Phone: 615-936-8544
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Molecular profiling to improve risk stratification in appendiceal cancer
Researchers test DNA methylation and m6A epitranscriptomic features in archived appendiceal cancer tissue to see if molecular subtypes and risk scores can better predict outcomes.
-
Paclitaxel given inside the abdomen with systemic therapy for GI cancers with peritoneal spread
This phase II study tests a combination of intraperitoneal and systemic chemotherapy (paclitaxel) in adults with digestive tract cancers that have spread to the peritoneum.
-
Appendix Cancer and PMP Patient Registry and Natural History Study
This global, patient-powered registry tests how appendix cancer and pseudomyxoma peritonei progress over time by collecting real-world data from patients and caregivers.
-
Metformin in PMP from appendiceal mucinous neoplasms
This pilot study tests whether metformin is feasible to use in adults with pseudomyxoma peritonei caused by appendiceal mucinous tumors who have recurrent or unresected disease.
-
TLR9-based immunotherapy for peritoneal cancer with ascites
This trial tests ACM-CpG injections into the abdomen to see if it’s safe and can help people with peritoneal metastases or malignant ascites from colorectal or appendiceal cancer.
-
Mass-based drug screening to guide personalized HIPEC for high-grade appendiceal and colorectal cancer with peritoneal spread.
This tests whether a lab-based mass response test on tumor biopsies can pick the best chemotherapy to use during repeated HIPEC for people with unresectable peritoneal metastases from high-grade appendiceal or colorectal cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.